Dr Francesca Gay speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the classification and detection of aggressive disease.
She describes the prognostic features of this disease such as cytogenetics, presence of extramedullary disease and disease presentation, along with other factors that are used to evaluate aggressiveness.
Dr Gay also discusses the definition of aggressive disease, along with the therapy options available for these patients - in which precision medicine could play a role.
In terms of the future, she believes an improved strategy is needed, that takes factors such as prognostic features and response rates into account.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.